OncoSec Email Formats

Biotechnology Research • San Diego, California, United States • 21-50 Employees

OncoSec Email Formats

OncoSec uses 4 email formats. The most common is {2char} (e.g., {2char}@oncosec.com), used 25% of the time.

Format	Example	Percentage
{2char}	{2char}@oncosec.com	25%
{first initial}{last name}	jdoe@oncosec.com	25%
{first name}	john@oncosec.com	25%
{first name}.{last name}	john.doe@oncosec.com	25%

Key Contacts at OncoSec

Yi Cpa

Director Of Sec Reporting And Technical Accounting

Art Schroeder

Director, Quality Assurance & Regulatory Compliance Quality Management Representative

Jennifer Jamieson

Associate Director

Company overview

Headquarters	3536 General Atomics Ct, San Diego, California 92121, US
Phone number	+12315178
Websites	oncosec.com formanlaw.com
NAICS	541714
SIC	873
Keywords	Life Sciences, Clinical Development, Oncology, Cancer Treatment, Immunotherapy, Drug Development
Founded	2011
Employees	21-50
Socials

About OncoSec

OncoSec is a biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary DNA gene transfer technology, OncoSec seeks to deliver safer and more effective cancer treatments that can provide long-term benefits for patients who have limited or no available treatment options. OncoSec’s technology combines TAVO™ (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC). To date, preliminary study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. OncoSec plans to develop TAVO, along with other immunologic genes to treat other cancer indications. OncoSec has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for TAVO in metastatic melanoma. NASDAQ: $ONCS

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Director

Employees by Department

OncoSec has 11 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore OncoSec's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-06-16	14	$1,300,000

Funding Insights

$1,300,000

Total funding amount

$1,300,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

OncoSec is located in San Diego, California, US.

You can reach OncoSec at +12315178.

OncoSec was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

OncoSec has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

OncoSec has raised a total of $1,300,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.